NRSN
NeuroSense Therapeutics Ltd

3,598
Mkt Cap
$30.89M
Volume
158,277.00
52W High
$2.60
52W Low
$0.6801
PE Ratio
-1.78
NRSN Fundamentals
Price
$1.04
Prev Close
$1.00
Open
$1.01
50D MA
$0.931
Beta
0.73
Avg. Volume
275,562.45
EPS (Annual)
-$0.5489
P/B
9.35
Rev/Employee
$0.00
$18.98
Loading...
Loading...
News
all
press releases
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering...
PR Newswire·6d ago
News Placeholder
More News
News Placeholder
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., Jan. 21, 2026 Patent protection...
PR Newswire·25d ago
News Placeholder
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire CAMBRIDGE, Mass., Jan. 8, 2026...
PR Newswire·1mo ago
News Placeholder
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR...
PR Newswire·2mo ago
News Placeholder
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire CAMBRIDGE, Mass., Dec. 4, 2025 CAMBRIDGE, Mass...
PR Newswire·2mo ago
News Placeholder
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire CAMBRIDGE...
PR Newswire·3mo ago
<
...
1
>

Latest NRSN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.